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Abstract
Objective—Constrictive remodeling accounts for lumen loss in postangioplasty restenosis. Matrix
metalloproteinase-9 (MMP-9) has been shown to prevent constrictive remodeling in vivo. To
investigate potential mechanisms for this observation, we investigated the role of MMP-9 in smooth
muscle cell (SMC)-mediated collagen gel contraction, an in vitro model of constrictive remodeling.
Methods—Fischer rat SMCs were stably transfected with a construct-expressing rat-MMP-9 under
the control of a tetracycline (Tet)-off promoter. SMCs were seeded in type I collagen gels (2.4 mg/
ml) in the presence or not of tetracycline (1 μg/ml), and gel contraction was defined as the percentage
of retraction of the collagen gel. The depletion of MMP-9 was obtained by using siRNA targeting
MMP-9 mRNA or a blocking antibody.
Results—Gel contraction was significantly reduced at all times when MMP-9 was overexpressed
(Tet−) as compared with the control condition (Tet+). However, MMP-9 depletion of control (Tet+)
SMCs (using siRNA or antibody) also inhibited gel contraction. To resolve the apparent discrepancy
and determine if MMP-9 exerts a dose-dependent biphasic effect on gel contraction, conditioned
medium and purified rat-MMP-9 were prepared. Gel contraction was significantly increased by
addition of 0.8 ng/ml of MMP-9, while high concentrations of MMP-9 (≥100 ng/ml) inhibited
contraction. The addition of BB94 and TIMP-1 did not alter the inhibitory or stimulatory effect of
MMP-9.
Conclusions—Our data suggest that MMP-9, independent of its proteolytic function, has a
biphasic effect on SMC-mediated collagen gel contraction. Understanding the different roles of
MMP-9 should allow the development of better therapeutic strategies for restenotic vascular disease.
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1. Introduction
Arterial remodeling is an important aspect of atherosclerosis and restenosis after interventions
such as angioplasty. It has become the object of intense research since vascular remodeling is
one of the key processes regulating lumen diameter after vascular injury and since restenosis
is a major cause of morbidity in humans [1]. Expansive (outward or positive) remodeling helps
to maintain luminal cross-sectional area during early phases of atherosclerotic plaque growth,
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but constrictive (inward or negative) remodeling in late phases of plaque growth and after
angioplasty contributes to luminal narrowing. Multiple events may participate in remodeling,
including smooth muscle cell (SMC) proliferation and migration, apoptosis, and changes in
cell/matrix interactions [2–5]. Extracellular matrix degrading proteinases [e.g., matrix
metalloproteinases (MMPs)] modify matrix composition and properties, both facets being
essential for cell/matrix interactions. MMPs have been shown to be involved in arterial
remodeling using animal models [6,7]. Others and we previously demonstrated that MMP-9
prevents constrictive remodeling and is necessary for outward remodeling using different in
vivo models [8,9]. However, MMP-9 was also reported to be needed for constrictive
remodeling in a MMP-9 genetic deficiency mouse carotid tie-off model [10]. To understand
this apparent discrepancy, we investigated the effect of MMP-9 on SMC-mediated collagen
gel contraction, an in vitro model of constrictive remodeling. The use of this model is supported
by the significant contribution of tissue contraction in lumen constriction [11,12]. We have
found that MMP-9 has a biphasic effect on SMC-mediated collagen gel contraction. At low
concentrations, MMP-9 stimulates contraction, while at high concentrations, MMP-9 inhibits




siRNA for rat MMP-9 was purchased from Eurogentec (Seraing, Belgium). Collagen
(Vitrogen) was purchased from Collagen (Fremont, CA). An antibody against human MMP-9,
and cross reacting with rat-MMP-9, was purchased from The Binding Site (Birmingham, UK),
and other chemical reagents were purchased from Sigma (St. Louis, MO).
2.2. Cell Culture
Fischer 344 rat aortic smooth muscle cells [SMC(tTA-MMP-9)] stably transfected with tTA
protein and rat MMP-9, which are both under control of the Tet operator, were prepared, as
described previously [8], and in accordance with state and federal laws and under protocols
approved by the University of Washington Animal Care and Use Committee. Animal care
complied with the Guide for the Care and Use of Laboratory Animals issued by the Institute
of Laboratory Animal Resources (NIH publication 85–23, revised 1996). The transfected cells
express low levels of MMP-9 in the presence of tetracycline and high levels of MMP-9 in the
absence of tetracycline. The cells were maintained in DMEM with 10% calf serum and 1 μg/
ml tetracycline. To prepare conditioned medium, cells were washed twice with PBS and
maintained in 10% serum with or without tetracycline for 24 h. Cells were then washed three
times with PBS and maintained in medium without serum and with or without tetracycline.
After 48 h, conditioned medium was collected.
2.3. Assay for collagen gel contraction by SMCs
SMCs(tTA-MMP-9) were maintained in 10% serum with or without tetracycline for 24 h prior
to seeding in type I collagen at a final concentration of 2.5−105 cells/ml and 2.5 mg collagen/
ml. The mixture of cells and collagen was poured into 24-well tissue culture plates (1 ml per
well) that were precoated with 1% agarose and allowed to polymerize at 37 °C in a 5% CO2
incubator for 1 h. Then, 1 ml of DMEM with 10% serum with or without tetracycline was
added. Gel contraction was measured every 24 h by scanning the plates with a flat bed scanner
and determining area of the gel using NIH ImageQuant. The area of an empty well (2 cm2)
was measured as a reference.
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2.4. SMC proliferation, DNA quantification, and trypan blue exclusion test
After 2 and 5 days of gel contraction, 1 μCi/ml of [3H] thymidine was added to the medium
for 24 h. As a control, parallel SMC-gel cultures were subjected to three cycles of freezing at
−80 °C and thawing at 37 °C before radiolabeling. After radiolabeling, medium was removed
and 1 ml of 20% TCA was added overnight at 4 °C. Gels were then vacuum-collected on 0.45
μm filters (Millipore) and washed several times with cold 10% TCA. Filters were then
incubated overnight in 1 M NaOH at 37 °C. Solubilized radioactivity was measured by liquid
scintillation counting. DNA quantification within the SMC-populated collagen gel at day 6
was performed using DNA assay, as described by Labarca and Paigen [13]. The ratio between
living and dead cells was also determined using trypan blue exclusion test.
2.5. MMP-9 activity assay
To investigate the effect of metalloproteinase inhibitors (BB-94 and TIMP-1) as well as
MMP-9 antibody on rat-MMP-9 activity, in vitro activity assays were performed, as described
by Oltenfreiter et al. [14]. Briefly, the initial rate of cleavage of a fluorescent substrate Mca–
Pro–Leu–Gly–Leu–Dpa–Ala–Arg–NH2 (4.5 μM) by purified rat-MMP-9 (150 nM) previously
activated by using APMA ( p-aminophenylmercuric acetate, 1 mM) was measured over 20 min
in the absence or presence of MMP inhibitors (BB-94, 0–10 nM; TIMP-1, ratio TIMP-1/
MMP-9 of 2 and 20) or MMP-9 antibody (0–100 μg/ml). Results are expressed in percentage
of inhibition.
2.6. siRNA transfection
To inhibit MMP-9 synthesis, two 21-nucleotide RNAs were chemically synthesized and
purified by reverse-phase HPLC (Eurogentec). The sequences for MMP-9 were 5′-
CAUCACCUAUUGGAUCCAAdTdT-3′ and 5′-UUGGAUCCAAUAGGUGAUGdTdT-3′,
and for a scrambled control, they were 5′-AUACUUACGCACGCUCCAATT-3′ and 5′-
UUGGAGCGUGCGUAAGUAUTT-3′. Each pair of oligonucleotides was annealed at a
concentration of 20 μM in 10 mM Tris–HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA. SMCs at
50% confluence in 10-cm dishes were transfected with 5 nM siRNA, using the calcium
phosphate-precipitation procedure for 15 h [15]. Cells were used in the collagen gel contraction
assay 24 h after transfection.
2.7. Rat MMP-9 purification
Rat MMP-9 purification was performed using gelatin–Sepharose chromatography followed by
Con A–Sepharose affinity chromatography according to Morodomi et al. [16]. Briefly, serum-
free conditioned medium of rat SMC overexpressing MMP-9 was applied to a column of
gelatin–Sepharose equilibrated with TNC buffer [50 mM Tris–HCl (pH 7.5), 0.15 M NaCl, 10
mM CaCl2, 0.02% NaN3, 0.05% Brij 35]. After extensive washing, elution was performed
using 5% (v/v) DMSO in TNC buffer. The collected fractions were then applied to a Con A–
Sepharose column equilibrated with TNC buffer. After washing with TNC buffer, MMP-9 was
eluted in 1 M α-methyl-D-mannoside in TNC buffer. The purified samples were dialyzed against
DMEM and analysed by gelatin zymography and ELISA to confirm the depletion of MMP-2
and fibronectin, respectively, two other gelatin-binding proteins.
2.8. MMP-9 depletion of fetal calf serum by affinity chromatography
Gelatin–Sepharose chromatography in TNC buffer [50 mM Tris–HCl (pH 7.5), 0.15 M NaCl,
10 mM CaCl2, 0.02% NaN3, 0.05% Brij 35] was used to remove MMP-9 from fetal calf serum
according to Morodomi et al. [16]. The unbound fraction (MMP-2/MMP-9 depleted serum)
and the 5% DMSO elution fraction (mainly MMP-2 and MMP-9) were dialyzed against
DMEM.
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Equal amounts of conditioned medium from identical numbers of cells grown under serum-
free conditions for 48 h were loaded onto gelatin SDS polyacrylamide gels, and zymography
was performed as described [17].
2.10. Statistics
Results are given as mean ± S.E.M. of n independent experiments. Student’s t test or one-way
ANOVA were performed for comparisons between groups as indicated. P ≤ 0.05 was
considered as significant.
3. Results
3.1. Overexpression of MMP-9 inhibits collagen gel contraction by SMCs
In confirmation of a previous work [8], we observed that conditioned medium collected from
rat SMC(tTA-MMP-9) cells cultured in the absence of tetracycline (Tet−) showed a strong
expression of proMMP-9 (~103 kDa) compared to the expression of MMP-9 in the presence
of tetracycline (Tet+; Fig. 1). ProMMP-2 (doublet at ~67 kDa) was present and not altered by
tetracycline. Overnight incubation of gelatin zymograms in the activation buffer containing
tetracycline at doses up to 50 μg/ml did not demonstrate any significant effect of tetracycline
on MMP activity (data not shown).
To investigate the effect of the overexpression of MMP-9 on SMC contractile activity, we
performed a collagen gel contraction assay in the presence or absence of tetracycline. In control
conditions (Tet+), collagen gel contraction started after 2 days, while when MMP-9 was
overexpressed (Tet−), contraction began after 3 days (Fig. 2). Gel contraction was significantly
reduced at all times when MMP-9 was overexpressed.
A possible role for calf serum MMP-9 in SMC-mediated collagen gel contraction was then
examined. No significant difference was found in gel contraction when 10% normal serum,
10% MMP-9-depleted serum, or 10% reconstituted serum (depleted serum repleted with the
MMP-9 containing bound fraction) was used (data not shown).
To investigate a possible effect of MMP-9 on cell proliferation, we measured [3H] thymidine
incorporation into DNA by SMC either overexpressing MMP-9 (Tet−) or not (Tet+). There
was no significant difference in the DNA synthesis by SMCs in collagen gels between the two
experimental conditions at days 2 and 5 (day 2: 128,955 ± 4953 and 129,027 ± 39,109 CPM,
Tet− and Tet+, respectively; day 5: 170,526 ± 2162 and 181,510 ± 31,869 CPM, Tet− and Tet
+, respectively, n=3).
The effect of MMP-9 on cell death was also investigated by measuring total DNA and the
living cells/dead cells ratio after staining cells with trypan blue. There was no significant
difference in the amount of DNA in SMC-populated collagen gels between the Tet− and Tet
+ conditions at day 6 (483 ± 60 and 503 ± 75 ng of DNA, Tet− and Tet+, respectively, n=3).
The living cells/dead cells ratio in SMC-populated collagen gels did not vary significantly
between the two experimental conditions at day 6 (6 ± 2 and 7 ± 3, Tet− and Tet+, respectively,
n=3).
The specificity of the inhibitory effect of MMP-9 on gel contraction was investigated by using
an MMP-9 antibody and by knocking-down the MMP-9 mRNA with siRNA. The addition of
anti-MMP-9 (50–200 μg/ml) to SMCs overexpressing MMP-9 (Tet−) restored normal
contraction of the collagen gels with an optimal effect obtained with 100 μg/ml of antibody
(Fig. 3A). SMCs overexpressing MMP-9 (Tet−) were transfected with siRNA targeting
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MMP-9 mRNA. The level of MMP-9 was reduced to about 15% of the control level (siRNA
scramble) up to 3-day post transfection and to about 20% after 5 days of transfection (Fig. 2B).
The treatment by siRNA against MMP-9 restored collagen gel contraction to a level similar to
that observed with cells that do not overexpress MMP-9 (Tet+; Fig. 3C). Thus, blockade of
MMP-9 by two independent procedures reversed the inhibitory effect of MMP-9 on collagen
gel contraction.
Because it has been reported that MMP-9 is required for SMC-mediated collagen gel
contraction [18], we investigated the possibility that MMP-9 may play a different role when
expressed at normal or low levels. When anti-MMP-9 (50–200 μg/ml) was added to SMCs
expressing only low levels of endogenous MMP-9 (Tet+), collagen gel contraction was
significantly inhibited as compared to the IgG control group. Optimal inhibition of gel
contraction was obtained with 100 μg/ml of anti-MMP-9 (Fig. 4A). Similarly, treatment with
MMP-9 siRNA induced a significant decrease of collagen gel contraction by SMCs cultured
in the Tet+ condition (Fig. 4B).
3.2. Regulation of collagen gel contraction by MMP-9 is dose-dependent
Since MMP-9 seemed to inhibit (Fig. 3) or to stimulate (Fig. 4) collagen gel contraction
depending upon its concentration, a dose–response experiment was performed (Fig. 5).
Conditioned medium from rat-SMC overexpressing MMP-9 (Tet−) was diluted or
concentrated to achieve a wide concentration range of MMP-9 (0.8–300 ng/ml), as estimated
by comparative zymography under linear response conditions. The complete MMP-9 depleted
conditioned medium (0.0 ng/ml) was obtained from SMC treated both with tetracycline, to
repress the expression of recombinant MMP-9, and MMP-9 siRNA, to inhibit the low level of
endogenous MMP-9 synthesis. SMCs used for the gel contraction assay were treated to prevent
any MMP-9 production (MMP-9 siRNA pretreatment and Tet+ condition during the assay).
In these conditions, addition of increasing amounts of recombinant MMP-9 (0–300 ng/ml)
resulted in a bell-shaped dose–response curve (Fig. 5A). Collagen gel contraction by SMCs
was significantly increased by addition of 0.8 ng/ml MMP-9 compared to the absence of
MMP-9 but was inhibited by high concentrations of MMP-9. In addition, control-conditioned
medium, obtained from SMC treated with tetracycline, to repress expression of recombinant
MMP-9, and with scrambled siRNA (endogenous MMP-9 is not inhibited), did not
significantly alter collagen gel contraction compared with conditioned medium obtained from
SMCs treated only with tetracycline to repress expression of recombinant MMP-9 (day 6: 56
± 4% vs. 58 ± 5%, respectively). To evaluate whether the effects on gel contraction observed
with conditioned medium was specific to MMP-9 and independent of other factors, MMP-9
was purified from SMC(tTA-MMP9)-conditioned medium. Similar effects on collagen gel
contraction were observed with purified MMP-9 at concentrations of 0, 0.8, 50, and 100 ng/
ml (Fig. 5B). These results confirm that MMP-9 is responsible for the inhibitory or stimulatory
effects on SMC-mediated collagen gel contraction.
3.3. BB-94 and TIMP-1 do not reverse the inhibition of gel contraction by MMP-9
The contribution of the proteolytic activity of MMP-9 on gel contraction was investigated by
using the broad-spectrum MMPs inhibitor BB-94 and the physiological tissue inhibitor of
metalloproteinase-1 (TIMP-1). Fig. 6A demonstrates that BB-94 (5 μM) [19] and TIMP-1 with
a ratio TIMP-1/MMP-9 of 1 did not alter the inhibition of SMC-mediated collagen gel
contraction induced by MMP-9 overexpression. In addition, BB-94 and TIMP-1 did not alter
collagen gel contraction in the control (Tet+) condition. Similar results were observed with
higher doses of BB-94 (up to 20 μM) and of TIMP-1 (TIMP-1/MMP-9 ratio up to 50; data not
shown).
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To demonstrate the functionality of the MMP inhibitors as well as to investigate the effect of
MMP-9 antibody on MMP-9 activity in our model, activity assays were performed. BB-94 as
well as TIMP-1 inhibited the cleavage of the fluorescent substrate by APMA-activated MMP-9,
while the MMP-9 antibody did not affect MMP-9 activity (Fig. 6B). No activity was detected
when MMP-9 was not activated in vitro with APMA, confirming the absence of an activated
form of MMP-9 in our system.
4. Discussion
Arterial wall remodeling is one of the most important factors regulating lumen diameter in
early atherosclerosis and after angioplasty [20–23]. MMPs have been studied in relation to
nonatherosclerotic arterial geometrical remodeling in animal models. Inhibition of MMPs
resulted in impaired constrictive remodeling after balloon angioplasty [6,24,25] and in
impaired expansive remodeling after flow enhancement [26].
In this study, we have demonstrated that MMP-9 has a biphasic dose–response effect on SMC-
mediated collagen gel contraction in vitro, with low concentrations increasing and high
concentrations decreasing contraction. These observations offer an explanation for the apparent
discrepancy between our previous observation that MMP-9 enhances positive remodeling in
vivo and the observation of Galis et al. [10] showing that MMP-9 mediates constrictive
remodeling in vivo. Interestingly, Godin et al. [27] showed that a significant increase in MMP-9
expression preceded positive geometrical remodeling in the mouse flow cessation model,
although this was not observed using another mouse strain [10].
Our observations are also of interest because concentrations of MMP-9 that we found to inhibit
collagen gel contraction in our model (≥ 100 ng/ml) are observed in the coronary wall with
unstable plaque [28] and in human blood under various circumstances including intense
atherosclerosis [29]. Thus, it is possible that MMP-9 may mediate the positive arterial
remodeling that is observed in conditions in which MMP-9 is present at high concentrations.
For example, MMP-9 is observed at higher levels in positively remodeled segments of
atherosclerotic arteries than in constrictively remodeled segments [30]. We also showed that
when MMP-9 is absent, the ability of SMC to contract collagen gels is impaired. These results
confirm and extend previous observations that low amounts of MMP-9 increased the
contraction of collagen gels by SMCs as compared to a complete depletion of MMP-9 [18].
Of particular interest is the observation that the proteolytic activity of MMP-9 is not required
for the biphasic dose–response effect on collagen contraction. Not only did BB94 and TIMP-1
not reverse the inhibitory effect of high levels of MMP-9, they also did not alter contraction
in the presence of endogenous levels of MMP-9 (+Tet conditions). These data suggest that
both the stimulatory and the inhibitory properties of MMP-9 on collagen gel contraction do
not require proteolytic activity. It has become clear in recent years that MMPs can affect cells
by mechanisms other than degradation of extracellular matrix proteins [31]. For example,
MMP-2 binds to αvβ3 [32,33] and β1 [33] integrins. The inhibition of contraction by MMP-9
independently of its proteolytic activity observed in our study reinforces the concept that MMPs
are much more than simply enzymes involved in the destruction of the ECM.
MMP-9 may modulate SMC contraction of collagen gels independently of its proteolytic
function through several mechanisms. First, CD44, a receptor for hyaluronan, plays a role in
SMC-mediated collagen gel contraction [18,34]. Yu and Stamenkovic [35] demonstrated that
MMP-9 binds to CD44 in vitro. Similarly, Johnson and Galis [18] showed in situ that MMP-9
and CD44 colocalize within the arterial wall. They also demonstrated that CD44 and MMP-9
are necessary for SMC-matrix interactions. Therefore, MMP-9 may act as a bridge between
the cell surface and the ECM as suggested by Johnson and Galis [18]. Complete depletion of
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MMP-9 may inhibit gel contraction, while elevated MMP-9 may saturate the receptor CD44
as well as the pericellular collagen, impairing interactions of CD44, MMP-9, and collagen.
Second, the β1 integrins are critical for contraction of a collagen matrix, as blocking antibodies
specific for α2β1 prevent contraction in vitro [36–38]. Since MMP-9 may bind to β1 integrin
[39], a competition between MMP-9 and collagen for this integrin may occur, leading to
reduced collagen gel contraction. Finally, Nassar et al. [40,41] showed that low density
lipoprotein-related receptor (LRP) mediates Ca2+ mobilisation and contraction of SMC.
Similar results were obtained using human fibroblasts [42]. Since MMP-9 is a ligand for LRP
[43], overexpression of MMP-9 may inhibit SMC contraction by blocking LRP-mediated
Ca2+ entry.
Our observations demonstrate that while low levels of MMP-9 promote SMC/ECM
contraction, high levels inhibit this process. Interestingly, although MMPs are now known to
have numerous substrates in addition to ECM molecules [44], these effects on gel contraction
appear to be independent of MMP-9 proteolytic activity. Up-regulation of MMP-9 seen after
vascular injury may modify the contractile ability of SMCs resulting in positive remodeling,
an initial beneficial phase after vascular injury. A better understanding of such a new function
of MMP-9 is necessary to develop adequate therapeutic strategies for vascular disease.
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Gelatin zymography of serum-free medium conditioned 48 h by cells transfected with
tetracycline-driven rat MMP-9 in the presence (Tet+) or absence (Tet−) of tetracycline and
concentrated 20-fold. Gelatinolytic activity is indicated by clear zones against a dark
background of stained substrate.
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Overexpression of MMP-9 inhibits collagen gel contraction by rat SMC. Effect of
overexpression of MMP-9 (Tet−) on collagen gel contraction by rat-SMC(tTA-MMP-9). The
illustration of the collagen gel contractions in Tet+ and Tet− condition is representative of a
day 6 situation. Data are expressed as percent of gel contraction. *P < 0.05 (n=4).
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Reversal of MMP-9-mediated inhibition of collagen gel contraction by an MMP-9 antibody
or siRNA targeting MMP-9 mRNA. (A) After gel polymerization, culture medium containing
100 μg/ml of anti-MMP-9, or nonimmune IgG was added in the absence of tetracycline (Tet
−), and gel contraction was measured. Control IgG (100 μg/ml) was also tested in the presence
of tetracycline. Data are expressed as the percent of gel contraction. *Anti-MMP-9 vs. IgG,
P < 0.05 (n=3). (B) Gelatin zymography of serum-free medium conditioned 24 h in the absence
of tetracycline by cells transfected with siRNA targeting MMP-9 mRNA or scrambled siRNA
(5 nM) 3 and 5 days after transfection. (C) Level of collagen gel contraction by cells in Tet+
condition or by cells transfected with siRNA targeting MMP-9 mRNA or scrambled siRNA
(5 nM) in Tet− conditions. Data are expressed as percent of gel contraction. *siMMP-9 vs.
siSC, P < 0.05 (n=3).
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The complete knock-down of MMP-9 inhibits collagen gel contraction by rat SMC(tTA-
MMP-9). (A) After gel polymerization, culture medium containing 100 μg/ml of anti-MMP-9
or control IgG was added in the presence of tetracycline (Tet+), and the level of collagen gel
contraction was measured. Data are expressed as percent of gel contraction. *anti-MMP-9 vs.
IgG, P < 0.05 (n=3). (B) Level of collagen gel contraction by cells transfected with siRNA
targeting MMP-9 mRNA or scrambled siRNA (5 nM) or not transfected in the Tet+ condition.
Data are expressed as percent of gel contraction. *siMMP-9 vs. siSC, P < 0.05 (n=3).
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The regulation of collagen gel contraction by MMP-9 is dose-dependent. (A) Conditioned
medium from rat SMC(tTA-MMP-9) over-expressing MMP-9 (Tet−) was diluted or
concentrated to achieve a wide range of MMP-9 (0–300 ng/ml), as demonstrated by
zymography. Collagen gel contraction by SMC treated to prevent any MMP-9 production
(MMP-9 siRNA transfection and Tet+ condition) was then measured in the presence of
conditioned medium containing increasing concentration of MMP-9. Data are expressed as
percent of gel contraction at day 6. *P < 0.05 (n=3). (B) Collagen gel contraction by SMCs
treated to prevent any MMP-9 production (MMP-9 siRNA transfection and Tet+ condition)
was measured in presence of purified rat MMP-9 (0, 0.8, 50, and 100 ng/ml). Data are expressed
as percent of gel contraction at day 6. *P < 0.05 (n=3).
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BB-94 and TIMP-1 do not impair the inhibition of collagen gel contraction by MMP-9. (A)
After gel polymerization, DMEM with 10% MMP-9-depleted serum, with (Tet+) or without
(Tet−) tetracycline, and with BB94 (5 μM) or TIMP-1 (ratio TIMP-1/MMP-9 of 1) or DMSO
was added, and the level of collagen gel contraction was measured. Data are expressed as
percent of gel contraction. *Tet− vs. Tet+ condition, P < 0.05 (n=3). (B) Effect of
metalloproteinase inhibitors (BB-94 and TIMP-1) and MMP-9 antibody on rat-MMP-9
enzymatic activity was investigated using in vitro activity assays, as described in Methods.
Results are expressed in percentage of inhibition.
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